JNJ-8377 / J&J - LARVOL DELTA

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=160 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Oct 2027 ➔ Sep 2028

Trial completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Johnson & Johnson’s “Class 1 Anti-tumor New Drug“ is approved for clinical trials in China [Google translation] (Anhui Huayuan Pharmaceutical E-commerce) - "According to the official website of CDE, Johnson & Johnson (China) Investment Co., Ltd...has obtained implicit approval for clinical trials for its Class 1 new chemical drug JNJ-88998377 oral tablets, which is indicated for B-cell non-Hodgkin's lymphoma (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], mucosa-associated lymphoid tissue lymphoma [MALTlymphoma], follicular lymphoma [FL], Waldenstrom's macroglobulinemia [WM])...This study is a Phase I clinical dose-escalation study of JNJ-88998377 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). It plans to enroll 160 people and is expected to be completed in 2027....After the clinical trial application of JNJ-88998377 is successfully approved by CDE, Johnson & Johnson may start further research on it in China."

New P1 trial • Trial completion date • Trial status • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=160 | Recruiting | Sponsor: Janssen Research & Development, LLC

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology